- Home
- PRFX vs INM Comparison
PRFX vs INM Comparison
Compare PRFX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- INM
- Stock Information
- Founded
- PRFX 2007
- INM 1981
- Country
- PRFX Israel
- INM Canada
- Employees
- PRFX N/A
- INM N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- INM Health Care
- Exchange
- PRFX Nasdaq
- INM Nasdaq
- Market Cap
- PRFX 3.8M
- INM 3.2M
- IPO Year
- PRFX 2020
- INM N/A
- Fundamental
- Price
- PRFX $2.32
- INM $2.98
- Analyst Decision
- PRFX Hold
- INM
- Analyst Count
- PRFX 1
- INM 0
- Target Price
- PRFX N/A
- INM N/A
- AVG Volume (30 Days)
- PRFX 3.8M
- INM 55.8K
- Earning Date
- PRFX 05-14-2025
- INM 05-13-2025
- Dividend Yield
- PRFX N/A
- INM N/A
- EPS Growth
- PRFX N/A
- INM N/A
- EPS
- PRFX N/A
- INM N/A
- Revenue
- PRFX N/A
- INM $4,832,013.00
- Revenue This Year
- PRFX N/A
- INM N/A
- Revenue Next Year
- PRFX N/A
- INM N/A
- P/E Ratio
- PRFX N/A
- INM N/A
- Revenue Growth
- PRFX N/A
- INM N/A
- 52 Week Low
- PRFX $0.43
- INM $1.72
- 52 Week High
- PRFX $16.63
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- PRFX 51.08
- INM 60.92
- Support Level
- PRFX $1.92
- INM $2.56
- Resistance Level
- PRFX $2.37
- INM $3.15
- Average True Range (ATR)
- PRFX 0.27
- INM 0.28
- MACD
- PRFX 0.07
- INM 0.09
- Stochastic Oscillator
- PRFX 35.36
- INM 88.11
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.